MA55797A - Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19 - Google Patents

Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19

Info

Publication number
MA55797A
MA55797A MA055797A MA55797A MA55797A MA 55797 A MA55797 A MA 55797A MA 055797 A MA055797 A MA 055797A MA 55797 A MA55797 A MA 55797A MA 55797 A MA55797 A MA 55797A
Authority
MA
Morocco
Prior art keywords
malignities
lymphocyte
genetically modified
cell therapy
allogenic cell
Prior art date
Application number
MA055797A
Other languages
English (en)
Inventor
Mark Benton
Tony Ho
Demetrios Kalaitzidis
Ewelina Morawa
Jonathan Alexander Terrett
Original Assignee
Crispr Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crispr Therapeutics Ag filed Critical Crispr Therapeutics Ag
Publication of MA55797A publication Critical patent/MA55797A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
MA055797A 2019-04-30 2020-04-30 Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19 MA55797A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962840913P 2019-04-30 2019-04-30

Publications (1)

Publication Number Publication Date
MA55797A true MA55797A (fr) 2022-03-09

Family

ID=70614366

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055797A MA55797A (fr) 2019-04-30 2020-04-30 Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19

Country Status (14)

Country Link
US (2) US20220249558A1 (fr)
EP (1) EP3962535A1 (fr)
JP (1) JP2022531185A (fr)
KR (1) KR20220003586A (fr)
CN (1) CN113939319A (fr)
AU (1) AU2020267057A1 (fr)
BR (1) BR112021021542A2 (fr)
CA (1) CA3138633A1 (fr)
EA (1) EA202192975A1 (fr)
IL (1) IL287482A (fr)
MA (1) MA55797A (fr)
MX (1) MX2021013359A (fr)
SG (1) SG11202112032WA (fr)
WO (1) WO2020222176A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023546178A (ja) * 2020-10-20 2023-11-01 クリスパー セラピューティクス アクチェンゲゼルシャフト Ｃｄ１９を標的とする遺伝子操作されたｔ細胞を用いたｂ細胞悪性腫瘍の同種他家細胞療法
WO2022098756A1 (fr) * 2020-11-03 2022-05-12 WUGEN, Inc. Thérapie par cellule à récepteur antigénique chimérique
CA3203531A1 (fr) 2020-12-30 2022-07-07 Simon Olivares Vecteurs recombinants comprenant des cassettes d'expression polycistronique et leurs procedes d'utilisation

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
EE05673B1 (et) 1999-08-17 2013-08-15 Biogen, Inc. BAFF-retseptor (BCMA), immunoregulatoorne agens
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
EP1460088A1 (fr) 2003-03-21 2004-09-22 Biotest AG Anticorps humanisé contre CD4 avec des caractéristiques immunosuppressives
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20120294863A1 (en) 2004-10-15 2012-11-22 Seattle Genetics, Inc. Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders
US7491390B2 (en) 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
ES2766123T3 (es) 2004-12-10 2020-06-11 Peter Maccallum Cancer Inst Métodos y composiciones para inmunoterapia adoptiva
EP1871418B1 (fr) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Agents de liaison anti-cd70 humanises et utilisations
CN103145842A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
US8124738B2 (en) 2005-09-26 2012-02-28 Medarex, Inc. Human monoclonal antibodies to CD70
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US7771720B2 (en) 2007-09-07 2010-08-10 Cisthera, Inc. Humanized PAI-1 antibodies
ES2588194T3 (es) 2008-04-11 2016-10-31 Seattle Genetics, Inc. Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres
CN102007147B (zh) 2008-06-30 2014-11-05 协和发酵麒麟株式会社 抗cd27抗体
CA2753158A1 (fr) * 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Anticorps humanises qui se fixent au cd19 et leurs utilisations
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
KR101773216B1 (ko) 2009-12-29 2017-08-31 교와 핫꼬 기린 가부시키가이샤 항 ｃｄ27 항체
PL2542590T5 (pl) 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
KR101958753B1 (ko) 2010-04-13 2019-03-15 셀덱스 쎄라퓨틱스, 인크. 인간 ｃｄ27에 결합하는 항체 및 이의 용도
US20120213771A1 (en) 2010-04-13 2012-08-23 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
JP6023706B2 (ja) 2010-07-09 2016-11-09 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ２７に対するアゴニスト抗体
CA2816379A1 (fr) 2010-10-27 2012-05-03 Baylor College Of Medicine Recepteurs cd27 chimeres utilises pour rediriger des lymphocytes t vers des tumeurs malignes positives pour cd70
NZ612512A (en) 2010-12-09 2015-03-27 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2828753C (fr) 2011-03-16 2022-07-26 arGEN-X BV Anticorps diriges contre cd70
PL3415531T3 (pl) 2011-05-27 2024-02-26 Glaxo Group Limited Białka wiążące antygen
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
CN104053672A (zh) 2011-11-11 2014-09-17 瑞纳神经科学公司 Trop-2特异性抗体及其用途
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
KR20130060720A (ko) 2011-11-30 2013-06-10 한국전자통신연구원 목적 기반 시맨틱 서비스 디스커버리를 위한 서비스 목적 해석 장치 및 방법
KR102153374B1 (ko) 2012-03-15 2020-09-10 얀센 바이오테크 인코포레이티드 인간 항-cd27 항체, 방법 및 용도
EP3689383A1 (fr) 2012-04-11 2020-08-05 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Récepteurs antigéniques chimériques ciblant un antigène de maturation des lymphocytes b
EP2855667B1 (fr) 2012-05-25 2023-08-09 Cellectis Procédés pour modifier des lymphocytes t allogéniques et résistants à l'immunosuppression pour l'immunothérapie
EP2914628A1 (fr) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin Anticorps qui se lie à cd269 (bcma) pouvant être utilisé dans le traitement de maladies des cellules plasmatiques comme le myélome multiple et les maladies auto-immunes
US10077315B2 (en) 2013-02-05 2018-09-18 Engmab Sàrl Bispecific antibodies against CD3 and BCMA
WO2014158821A1 (fr) 2013-03-12 2014-10-02 Imaginab, Inc. Constructions de liaison d'antigène à cd70
MX2015011367A (es) 2013-03-13 2015-12-16 Seattle Genetics Inc Ciclodextrina y formulaciones de conjugados anticuerpo-farmaco.
WO2014140374A2 (fr) 2013-03-15 2014-09-18 Novo Nordisk A/S Anticorps monovalents anti-cd27
AU2014235968B2 (en) 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
JP2016522679A (ja) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
AU2014273490B2 (en) 2013-05-29 2019-05-09 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
TWM466588U (zh) * 2013-07-31 2013-12-01 Guo-Chang Wu 嬰兒金屬床架
US20150344844A1 (en) 2014-02-04 2015-12-03 Marc Better Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
BR112016017806B1 (pt) 2014-02-14 2023-05-02 Cellectis Uso de células t engenheiradas para imunoterapia contra células patológicas, e método ex vivo para preparação das mesmas
EP3114217A4 (fr) 2014-03-07 2017-09-20 Bellicum Pharmaceuticals, Inc. Polypeptides de type caspase à activité modifiée et leurs utilisations
WO2015136001A1 (fr) 2014-03-11 2015-09-17 Cellectis Procédé d'obtention de lymphocytes t compatibles avec la transplantation allogénique
EP3119423B1 (fr) 2014-03-15 2022-12-14 Novartis AG Traitement du cancer avec un récepteur d'antigène chimérique
EP3131927B8 (fr) 2014-04-14 2020-12-23 Cellectis Récepteurs antigéniques chimériques spécifiques de bcma (cd269), utiles dans l'immunothérapie du cancer
SG10201809157VA (en) 2014-04-18 2018-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
SG11201609960QA (en) * 2014-06-02 2016-12-29 Us Health Chimeric antigen receptors targeting cd-19
WO2015188065A1 (fr) 2014-06-05 2015-12-10 Sangamo Biosciences, Inc. Méthodes et compositions pour conception de nucléases
EP3172237A2 (fr) 2014-07-21 2017-05-31 Novartis AG Traitement du cancer au moyen d'un récepteur d'antigène chimérique anti-bcma humanisé
AU2015292590B2 (en) 2014-07-24 2020-01-16 2Seventy Bio, Inc. BCMA chimeric antigen receptors
JP2017524365A (ja) 2014-08-12 2017-08-31 アントフロゲネシス コーポレーション リンパ節のｂ細胞領域、皮膚、または腸管にホーミングするように操作されたｃａｒ−ｔ細胞
WO2016049385A1 (fr) * 2014-09-24 2016-03-31 Apellis Pharmaceuticals, Inc. Méthodes et compositions destinées à traiter le cancer et choix du traitement
GB201418965D0 (fr) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
KR20230098910A (ko) 2014-10-31 2023-07-04 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
WO2016073955A2 (fr) 2014-11-06 2016-05-12 President And Fellows Of Harvard College Cellules ne présentant pas d'expression en surface de b2m et procédés pour l'administration allogène de ces cellules
WO2016089433A1 (fr) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Arn guide comportant des modifications chimiques
CN113698497A (zh) 2014-12-05 2021-11-26 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
LT3628687T (lt) 2014-12-12 2021-11-10 2Seventy Bio, Inc. Chimeriniai bcma antigeno receptoriai
IL302660A (en) 2014-12-19 2023-07-01 Dana Farber Cancer Inst Inc Chimeric antigen receptors and methods of using them
WO2016120220A1 (fr) 2015-01-26 2016-08-04 Cellectis Cellules immunocompétentes à modification tcr ko dotées de récepteurs d'antigènes chimériques se liant à cd123, pour le traitement de la leucémie myéloïde aiguë réfractaire ou récidivante ou du néoplasme à cellules dendritiques plasmacytoïdes blastiques
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
CN107847524A (zh) 2015-03-27 2018-03-27 哈佛学院校长同事会 经过修饰的t细胞及其制备和使用方法
EP3280803B1 (fr) 2015-04-06 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Arn guides chimiquement modifiés pour la régulation génétique médiée par crispr/cas
US10253086B2 (en) 2015-04-08 2019-04-09 Novartis Ag CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
WO2016174652A1 (fr) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Récepteurs antigéniques chimériques et méthodes d'utilisation correspondantes
JP2018515139A (ja) 2015-05-08 2018-06-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 万能ドナー幹細胞および関連する方法
SG10201914069SA (en) 2015-05-18 2020-03-30 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using fusion proteins
EP3328399B1 (fr) 2015-07-31 2023-12-27 Regents of the University of Minnesota Cellules modifiées et méthodes de thérapie
EP3858388A1 (fr) 2015-09-28 2021-08-04 Regents of the University of Minnesota Lymphocytes t de type récepteur d'antigène chimérique (car) en tant qu'interventions thérapeutiques d'auto- et d'allo-immunité
DK3756682T3 (da) 2015-10-05 2022-07-11 Prec Biosciences Inc Genetisk modificerede celler, der omfatter et modificeret gen fra det konstante område af den humane t-cellereceptor alpha
GB201518136D0 (en) 2015-10-14 2015-11-25 Glaxosmithkline Ip Dev Ltd Novel chimeric antigen receptors
WO2017070429A1 (fr) 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Procédés consistant à éditer des polynucléotides codant pour un récepteur de lymphocytes t
JP7115982B2 (ja) 2015-10-30 2022-08-09 アレタ・バイオセラピューティクス・インコーポレイテッド 癌の治療のための組成物及び方法
KR20190008171A (ko) 2015-11-13 2019-01-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항-bcma 폴리펩티드 및 단백질
EP3384027A1 (fr) 2015-12-04 2018-10-10 Novartis AG Compositions et procédés d'immuno-oncologie
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
CN108778297B (zh) 2015-12-18 2024-02-09 桑格摩生物治疗股份有限公司 T细胞受体的靶向破坏
CA3008382A1 (fr) 2015-12-18 2017-06-22 Sangamo Therapeutics, Inc. Disruption ciblee du recepteur des cellules du cmh
EP3394253B1 (fr) 2015-12-23 2021-09-01 Precision Biosciences, Inc. Méganucléases génétiquement modifiées comportant des séquences de reconnaissance que l'on trouve dans le gène de la microglobuline bêta-2 humaine
ITUB20160112A1 (it) 2016-01-28 2016-04-28 Serteaweb Srl Processo di allarme e sistema televisivo relativo ad un tale processo di allarme
US20170233484A1 (en) 2016-02-17 2017-08-17 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
RU2018134771A (ru) 2016-03-04 2020-04-06 Новартис Аг Клетки, экспрессирующие множество молекул химерных антигенных рецепторов (car), и их применение
BR112018068354A2 (pt) 2016-03-11 2019-01-15 Bluebird Bio Inc células efetoras imunológicas do genoma editado
BR112018070073A2 (pt) 2016-04-01 2019-02-12 Kite Pharma, Inc. receptores de antígeno quimérico e célula t e métodos de uso
CN113082201A (zh) 2016-04-01 2021-07-09 上海斯丹赛生物技术有限公司 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
CA3020330A1 (fr) 2016-04-07 2017-10-12 Bluebird Bio, Inc. Compositions de lymphocytes t recepteurs d'antigenes chimeriques
JP7125351B2 (ja) 2016-04-14 2022-08-24 ２セブンティ バイオ インコーポレイテッド サルベージキメラ抗原受容体システム
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
EP3448427A1 (fr) 2016-04-29 2019-03-06 CureVac AG Arn codant pour un anticorps
WO2017189959A1 (fr) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
WO2017210617A2 (fr) 2016-06-02 2017-12-07 Porter, David, L. Régimes thérapeutiques pour cellules exprimant un récepteur antigénique chimérique (car)
SG10202012157QA (en) 2016-06-07 2021-01-28 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
DE102016211884A1 (de) 2016-06-30 2018-01-04 Zf Friedrichshafen Ag Getriebe für ein Kraftfahrzeug, sowie Antriebsstrang für ein Kraftfahrzeug
WO2018068257A1 (fr) 2016-10-13 2018-04-19 北京艺妙神州医疗科技有限公司 Cellule car-t universelle et procédé pour sa préparation et application correspondante
WO2018073391A1 (fr) 2016-10-19 2018-04-26 Cellectis Insertion de gènes cibles pour immunothérapie cellulaire améliorée
WO2018073393A2 (fr) 2016-10-19 2018-04-26 Cellectis Cellules allogéniques modifiées par une nucléase d'effecteur tal (talen) appropriées pour une thérapie
CN110268050A (zh) 2017-01-10 2019-09-20 综合医院公司 经修饰的t细胞和它们的使用方法
BR112019021857A2 (pt) 2017-04-19 2020-06-02 Allogene Therapeutics, Inc. Métodos e composições de célula t aperfeiçoada
AU2018367896B2 (en) * 2017-05-12 2023-06-01 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CN107392652A (zh) 2017-06-30 2017-11-24 广州市中崎商业机器股份有限公司 基于收银纸背面进行针对性广告发布的系统及方法
CA3084470A1 (fr) * 2017-10-18 2019-04-25 Kite Pharma, Inc. Procedes d'administration d'immunotherapie de recepteur d'antigene chimerique
CN111511903A (zh) 2017-10-19 2020-08-07 塞勒克提斯公司 用于改善的免疫细胞疗法的nk抑制剂基因的靶向基因整合
KR20200094147A (ko) 2017-10-31 2020-08-06 알로젠 테라퓨틱스 인코포레이티드 동종이계 키메라 항원 수용체 t 세포를 투여하기 위한 방법 및 조성물
JP2021522820A (ja) 2018-05-11 2021-09-02 クリスパー セラピューティクス アクチェンゲゼルシャフト 癌を治療するための方法及び組成物
US20200085869A1 (en) 2018-05-16 2020-03-19 Novartis Ag Therapeutic regimens for chimeric antigen receptor therapies
GB201903229D0 (en) 2019-03-11 2019-04-24 Autolus Ltd Immunotherapy

Also Published As

Publication number Publication date
US20210268026A1 (en) 2021-09-02
CA3138633A1 (fr) 2020-11-05
CN113939319A (zh) 2022-01-14
KR20220003586A (ko) 2022-01-10
IL287482A (en) 2021-12-01
AU2020267057A1 (en) 2021-11-18
WO2020222176A1 (fr) 2020-11-05
EA202192975A1 (ru) 2022-02-01
BR112021021542A2 (pt) 2022-04-19
MX2021013359A (es) 2022-01-31
SG11202112032WA (en) 2021-11-29
US20220249558A1 (en) 2022-08-11
JP2022531185A (ja) 2022-07-06
US11389481B2 (en) 2022-07-19
EP3962535A1 (fr) 2022-03-09

Similar Documents

Publication Publication Date Title
MA55797A (fr) Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19
MA54952A (fr) Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
MA46716A (fr) Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA52662A (fr) Conjugués d'il-2
MA54704A (fr) Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA55312A (fr) Protection contre l'encrassement biologique
MA51915A (fr) Expression régulée de transgènes à l'aide de vecteurs adn à extrémités fermées (cedna)
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
MA53811A (fr) Anticorps spécifiques à l'apoc3 humaine et du cynomolgus et procédés pour leur utilisation
MA55799A (fr) Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
MA55911A (fr) Lymphocytes t génétiquement modifiés
MA55010A (fr) Système d'électrodes
MA52021A (fr) Anticorps anti-lif et leurs formes galéniques
DK3979827T3 (da) Næringssammensætning omfattende 2'fucosyllactose og 3'galactosyllactose
MA55528A (fr) Synthèse acellulaire optimisée d'antigène b de plasmide d'invasion, compositions associées et procédés d'utilisation
MA55815A (fr) Traitement de céphalées à l'aide d'anticorps anti-cgrp
MA51453A (fr) Conjugués anticorps anti-sez6-médicaments et procédés d'utilisation
MA52247A (fr) Conjugués phospholipide-flavagline et procédés d'utilisation de ceux-ci pour une thérapie anticancéreuse ciblée
MA52764A (fr) Anticorps anti-siglec-7 et leurs méthodes d'utilisation
MA56397A (fr) Protéines de liaison à l'il1rap
MA54937A (fr) Troubles induits par l'interféron de type i
MA52299A (fr) Procédés d'amélioration de la réponse à un traitement par anticorps anti-lif chez des individus atteints d'un cancer